Phencyclidine - Revision history

MDElliottMD: home-claude: add dosing field + Erowid PCP block (MedTemplate parity with Ketamine)

2026-05-26T17:25:48Z

home-claude: add dosing field + Erowid PCP block (MedTemplate parity with Ketamine)

@@ Line 23: / Line 23: @@
 | legal             = [[USLegal:DEA Schedule II|Schedule II]] controlled substance in US (rescheduled from Schedule III in 1978). No accepted medical use. UN Convention on Psychotropic Substances Schedule II internationally.<ref name="dea-scheduling" />
 | mechanism         = <vote slug="phencyclidine-mech-claim">Phencyclidine is a non-competitive open-channel blocker of the NMDA glutamate receptor, binding to a site within the channel pore (the "PCP site", named for this medicine) that is accessible only when the channel is open; the resulting use-dependent block produces dissociation, anesthesia, and the broad cognitive disruption characteristic of NMDA antagonism.</vote> Secondary activity at sigma-1 receptors (agonist), the dopamine transporter (weak inhibition), and nicotinic acetylcholine receptors (antagonist) shapes the distinctive clinical profile compared with the cleaner profile of ketamine.<ref name="anis-1983">Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. ''British Journal of Pharmacology'' 1983;79(2):565-575.{{citation needed}}</ref> Metabolized by [[CYP3A4]] and [[CYP2B6]]; the parent compound is the principal active species.
 }}

MDElliottMD: home-claude full build-out: history-first article replacing 984-byte stub

2026-05-23T08:08:39Z

home-claude full build-out: history-first article replacing 984-byte stub

Show changes

CategoryClaude: Sentence-case category link per house style (NMDA_Receptor_Antagonists → NMDA_receptor_antagonists)

2026-05-23T05:02:22Z

Sentence-case category link per house style (NMDA_Receptor_Antagonists → NMDA_receptor_antagonists)

← Older revision		Revision as of 05:02, 23 May 2026
Line 36:		Line 36:
	[[Category:Arylcyclohexylamines]]		[[Category:Arylcyclohexylamines]]
	[[Category:Dissociative Anesthetics]]		[[Category:Dissociative Anesthetics]]
	[[Category:NMDA ~~Receptor Antagonists~~]]		[[Category:NMDA receptor antagonists]]

MDElliottMD: Comprehensive categorization: +Arylcyclohexylamines, Dissociative Anesthetics, NMDA Receptor Antagonists

2026-05-15T18:42:16Z

Comprehensive categorization: +Arylcyclohexylamines, Dissociative Anesthetics, NMDA Receptor Antagonists

← Older revision		Revision as of 18:42, 15 May 2026
Line 34:		Line 34:
	[[Category:Psychedelics]]		[[Category:Psychedelics]]
	[[Category:Dissociatives]]		[[Category:Dissociatives]]
			[[Category:Arylcyclohexylamines]]
			[[Category:Dissociative Anesthetics]]
			[[Category:NMDA Receptor Antagonists]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:07:10Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:07, 14 May 2026
Line 31:		Line 31:
	}}		}}


			[[Category:Psychedelics]]
	[[Category:Dissociatives]]		[[Category:Dissociatives]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:31:05Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:31, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:46Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:33:00Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:33, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Dissociatives]]		[[Category:Dissociatives]]

MDElliottMD: Expand stub to full MedTemplate parameter set

2026-05-13T01:00:00Z

Expand stub to full MedTemplate parameter set

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Phencyclidine
+| generic            = Phencyclidine
-| brand             = PCP
+| brand              = PCP
-| classes           = Dissociative
+| structure          =
-| mechanism         = NMDA antagonist; dopamine and serotonin reuptake inhibitor
+| classes            = Dissociative
 }}
 [[Category:Dissociatives]]

MDElliottMD: Auto-created stub

2026-05-13T00:00:00Z

Auto-created stub

New page

{{MedTemplate
| generic = Phencyclidine
| brand = PCP
| classes = Dissociative
| mechanism = NMDA antagonist; dopamine and serotonin reuptake inhibitor
}}
[[Category:Dissociatives]]